Tenon Medical Earnings Call Highlights Growth And Risk

Tenon Medical, Inc. ((TNON)) has held its Q4 earnings call. Read on for the main highlights of the call.

Tenon Medical’s latest earnings call struck an optimistic tone on growth and execution, even as it acknowledged significant financial risks. Management highlighted record revenue, sharp gross margin gains, new FDA clearance for its SImmetry+ system, and fresh capital to extend runway. Yet the discussion underscored that net losses and a high burn rate leave little room for missteps as the company pushes toward broader commercialization.

Record Revenue Signals Building Commercial Momentum

Tenon reported full‑year revenue of $3.9 million, up 20% year over year, driven by accelerating adoption in the second half. Fourth‑quarter revenue reached $1.5 million versus $0.8 million a year earlier, a 92% surge that implies an annualized run‑rate near $6 million and suggests growing traction among spine surgeons.

Gross Margin Expansion Highlights Improving Economics

Profitability metrics showed notable progress, with fourth‑quarter gross profit climbing to $1.0 million for a 69% margin, up from $0.4 million and 46% in the prior‑year period. For the full year, gross profit rose 38% to $2.4 million, lifting gross margin to 60% and demonstrating that higher volume and better cost control are improving unit economics.

FDA Clearance for SImmetry+ Catalyzes Next Growth Phase

The company secured FDA 510(k) clearance for its next‑generation SImmetry+ SI‑Joint Fusion System and completed early clinical cases in the fourth quarter. Management said these initial procedures validate the system clinically and support the early stages of a broader commercial rollout aimed at deepening physician adoption and expanding use cases.

Fresh Capital Raises Extend Runway for Expansion

To back its growth plans, Tenon completed a $2.85 million at‑the‑market private investment in public equity during the quarter. After quarter end, it added a $4.3 million private placement of senior convertible notes, which together provide additional liquidity to fund sales expansion and clinical initiatives, albeit with new balance‑sheet complexity.

Operational Efficiencies Drive Cost of Sales Down

Management emphasized improvements in operational efficiency and lower cost of sales as key drivers of margin gains. Better field productivity and greater absorption of fixed manufacturing and logistics costs helped leverage existing infrastructure, supporting higher gross margins as procedure volumes increased.

Growing Physician Engagement Underpins Adoption Story

Commercial metrics were a bright spot, with the company hosting 24 physicians in targeted training sessions during the fourth quarter alone. Executives cited record levels of users and surgeries and described strong enthusiasm from clinicians for the expanding product portfolio, positioning Tenon to benefit from word‑of‑mouth and procedural familiarity.

Expanded Patent Estate Bolsters Competitive Moat

Tenon continued to build its intellectual property position, receiving notices of allowance on multiple patent applications. The company now counts 29 issued U.S. patents, nine international patents and 31 pending filings, adding legal protection around its technology and potentially strengthening its negotiating leverage with strategic partners.

Cash Decline Underscores Liquidity Sensitivity

Despite the capital raises, the call highlighted that cash and equivalents fell to $3.8 million at year‑end from $6.5 million a year earlier, a roughly 42% decline. This erosion underlines how dependent the company remains on external financing to bridge the gap between operating cash burn and still‑modest revenue.

Net Losses Narrow but Remain Substantial

On the bottom line, Tenon reported a full‑year net loss of $12.6 million, or $1.70 per share, improved from a $13.7 million loss the prior year. Fourth‑quarter net loss was $2.8 million, or $0.29 per share, reflecting better margins but still signaling that the business remains far from break‑even at current scale.

Operating Expenses Still Far Outpace Revenue

The company’s cost structure remains heavy, with 2025 operating expenses of $15.2 million versus $3.9 million in revenue, meaning opex is nearly four times annual sales. While that figure edged down from $15.5 million a year earlier, it underscores a high burn rate that will require rapid revenue ramp or continued financing to sustain.

Fourth‑Quarter Spend Ticks Up with Sales Effort

In the fourth quarter, operating expenses rose to $3.9 million from $3.5 million in the prior‑year period, an increase of roughly 11%. Management attributed the uptick mainly to higher variable sales and marketing spending to support increased procedure volumes and the early rollout of SImmetry+.

Execution Risk Tied to Commercialization Pace

Management stressed that future growth depends heavily on successfully commercializing SImmetry+ and other pipeline offerings while scaling physician adoption. The absence of formal revenue guidance and the emphasis on execution milestones signal that investors must closely watch adoption metrics, training activity, and procedure growth as leading indicators.

Financing Structure Raises Dilution Considerations

While the recent ATM PIPE and senior convertible notes improve liquidity, they also introduce potential dilution and leverage over time. Shareholders will need to weigh the benefits of extended runway and accelerated commercial investment against the impact of additional shares or conversions that could pressure per‑share metrics.

Outlook: Growth, Margin Gains and a Focus on Discipline

Looking ahead, Tenon expects continued revenue growth and further gross margin improvement as SImmetry+ and other launches scale through 2026. Management framed fourth‑quarter operating expenses as a baseline, signaling a focus on disciplined spending while leveraging recent capital, patent strength and physician engagement to drive adoption and work toward a more sustainable financial profile.

Tenon’s earnings call painted a picture of a company gaining commercial momentum and improving margins while still wrestling with sizable losses and liquidity risk. For investors, the story now hinges on whether management can convert regulatory wins, physician enthusiasm and new capital into durable revenue growth before the burn rate forces more costly financing moves.